Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, the analyst tells investors in a research note. More concerning is if demand for relacorilant, which is modeled to be a larger product, would be met if approved by December 30 PDUFA, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics: Strong Growth Potential and Promising Pipeline Support Buy Rating
- Corcept Therapeutics price target lowered to $145 from $150 at H.C. Wainwright
- Corcept Therapeutics Reports Q1 2025 Financial Results
- Closing Bell Movers: Palantir falls 9%, Ford down 2% on earnings
- Corcept Therapeutics reports Q1 EPS 17c, consensus 14c